Viridian Therapeutics, Inc.\DE (VRDN) Current Deferred Revenue: 2020-2025
Historic Current Deferred Revenue for Viridian Therapeutics, Inc.\DE (VRDN) over the last 4 years, with Jun 2025 value amounting to $288,000.
- Viridian Therapeutics, Inc.\DE's Current Deferred Revenue changed negligibly% to $288,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $288,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $288,000 for FY2024, which is negligibly% changed negligibly from last year.
- Viridian Therapeutics, Inc.\DE's Current Deferred Revenue amounted to $288,000 in Q2 2025, which was down 0.00% from $288,000 recorded in Q1 2025.
- Viridian Therapeutics, Inc.\DE's Current Deferred Revenue's 5-year high stood at $289,000 during Q4 2021, with a 5-year trough of $288,000 in Q1 2021.
- Over the past 3 years, Viridian Therapeutics, Inc.\DE's median Current Deferred Revenue value was $288,000 (recorded in 2025), while the average stood at $288,000.
- Data for Viridian Therapeutics, Inc.\DE's Current Deferred Revenue shows a maximum YoY decreased of 3.99% (in 2021) over the last 5 years.
- Quarterly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Current Deferred Revenue stood at $289,000 in 2021, then fell by 0.35% to $288,000 in 2022, then remained steady at $288,000 in 2023, then remained steady at $288,000 in 2024, then remained steady at $288,000 in 2025.
- Its Current Deferred Revenue stands at $288,000 for Q2 2025, versus $288,000 for Q1 2025 and $288,000 for Q4 2024.